Discussion
Pediatric unexplained chronic pain (UCP) presents a diagnostic and management challenge. Typically, families believe that UCP has solely an organic cause and frequently resist suggestions that psychosocial factors may be responsible for its development or perpetuation (1, 2, 6) . Consequently, such patients develop a pattern of help-seeking behaviour involving multiple diagnostic investigations, repeated emergency department visits, hospital admissions, and prolonged hospital stays (3) . Family physicians, pediatricians, and specialists in gastroenterology, rheumatology, endocrinology, and neurology are consulted frequently.
To address this problem, we have established a multidisciplinary, family-oriented, and rehabilitation-focused program to treat patients with UCP. We use a battery of psychosocial self-report scales to evaluate perfectionism, anxiety, and depressive symptoms (4, 5, 7) . Treatment goals focus on enhanced patient functioning (with emphasis on sleep, school attendance, and social interaction), rather than on the symptoms. The family is taught coping strategies for enhanced functioning. Existing similar programs are also oriented to coping and function rather to the pain symptoms (1) . A selective serotonin reuptake inhibitor is added to address anxious coping.
In a pilot study evaluating this program, we administered self-report scales to 15 patients (5 boys and 10 girls; mean age 12.4 years, SD 3.2) with a minimum of 3 months of UCP. The referring physician excluded significant organic pathology. Overall, we found that anxious coping styles and difficulty with separation were common among the referred population. Levels of perfectionism fell between those in a healthy control group (low) and those in a group with anorexia (high). Elevations occurred in the domains of feeling unsatisfied after completing projects, high personal standards, and the need for order. These results were psychoeducational in that they helped parents and patients focus on the rehabilitation goals and enhanced their confidence in a program that targets function, rather than pain.
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Hypokalemia from Risperidone and Quetiapine Overdose
Dear Editor: Hypokalemia has been listed as one of the known toxic effects of both quetiapine and risperidone. It is a risk factor for potentially life-threatening arrhythmias like torsades de pointes, caused by a prolonged QT interval-another side-effect of antipsychotic drugs, including quetiapine (1) . There is a solitary report of mild hypokalemia following a quetiapine overdose of 9600 mg (2) . Here, we report a case of remarkable hypokalemia following a much smaller dose of quetiapine and risperidone.
Case Report
Mr B, a white man aged 44 years, had a diagnosis of bipolar disorder not otherwise specified. He was taking risperidone 3 mg daily, lithium carbonate 900 mg daily, and quetiapine 50 mg at bedtime. At about 20:30 hours on the night of presentation, he attempted suicide by taking approximately 750 mg of quetiapine and between 90 and 120 mg of risperidone.
He denied taking lithium in his attempt. This was substantiated by a subsequent test that revealed a lithium level of 0.4 mmol/L. He presented to the emergency room about 2 hours after the ingestion and was stabilized medically. Initial labs drawn at the time of emergency department presentation showed potassium levels of 2.9 mmol/L and magnesium levels of 1.7 mg/dL (with lower normal levels being 1.8 mg/dL). His potassium level was initially corrected with intravenous cocktails in the emergency department and intensive care unit and was followed over the next few days. It subsequently plateaued and remained stable and in the normal range. Mr B recovered fully and was discharged home after a brief hospital stay.
Discussion
Both risperidone and quetiapine can cause hypokalemia. However, at about 350 mg or more, the risperidone dose reported to cause hypokalemia is much higher than that taken by Mr B. The previously reported case of hypokalemia following quetiapine overdose found a potassium level of 3.3 mmol/L after ingestion of 9600 mg (2) . Our patient ingested only about 750 mg of quetiapine and about 100 mg of risperidone. Could it be that the drugs acted synergistically to cause a more dramatic hypokalemia? Although exact mechanisms of action are not clear, it is possible that both drugs cause a more dramatic drop in serum potassium following acute ingestion, which would further increase the chances of torsades de pointes and sudden cardiac death secondary to concomitant QT interval prolongation.
This case demonstrates that we need to be vigilant after an apparently nonlethal overdose of 2 drugs having a relatively safe overdose profile, both for possible synergistic effects of the 2 drugs on serum electrolytes and for the possible ensuing complications.
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